Literature DB >> 15486491

Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801.

Fabio Fumagalli1, Raffaella Molteni, Francesco Bedogni, Massimo Gennarelli, Jorge Perez, Giorgio Racagni, Marco A Riva.   

Abstract

Fibroblast growth factor-2 (FGF-2) and brain-derived neurotrophic factor (BDNF) are trophic factors, widely distributed in the adult brain, whose expression can be modulated by psychoactive drugs. Administration of the atypical antipsychotic quetiapine resulted in a marked elevation of FGF-2 and BDNF mRNA levels in the rat hippocampus, but only under conditions of reduced NMDA receptor activity. These effects were drug-specific, given that they were not observed with the conventional antipsychotic haloperidol; and anatomically defined, since no similar effect was observed in striatum, prefrontal or frontal cortex. These results suggest that quetiapine may promote neuroplasticity via the up-regulation of neurotrophic factors when NMDA-mediated transmission is perturbed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15486491     DOI: 10.1097/00001756-200409150-00022

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  19 in total

Review 1.  Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Authors:  Jiri Horacek; Vera Bubenikova-Valesova; Milan Kopecek; Tomas Palenicek; Colleen Dockery; Pavel Mohr; Cyril Höschl
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 2.  Fibroblast growth factors in schizophrenia.

Authors:  Afke F Terwisscha van Scheltinga; Steven C Bakker; René S Kahn
Journal:  Schizophr Bull       Date:  2009-05-08       Impact factor: 9.306

Review 3.  Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models.

Authors:  Jue He; Jiming Kong; Qing-Rong Tan; Xin-Min Li
Journal:  Cell Adh Migr       Date:  2009-01-13       Impact factor: 3.405

Review 4.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

5.  Cabergoline, a dopamine receptor agonist, has an antidepressant-like property and enhances brain-derived neurotrophic factor signaling.

Authors:  Shuichi Chiba; Tadahiro Numakawa; Midori Ninomiya; Hyung Shin Yoon; Hiroshi Kunugi
Journal:  Psychopharmacology (Berl)       Date:  2010-06-05       Impact factor: 4.530

6.  Brain differences in first-episode schizophrenia treated with quetiapine: a deformation-based morphometric study.

Authors:  Chunlan Yang; Shuicai Wu; Wangsheng Lu; Yanping Bai; Hongjian Gao
Journal:  Psychopharmacology (Berl)       Date:  2014-08-02       Impact factor: 4.530

7.  Stress and cocaine interact to modulate Arc/Arg3.1 expression in rat brain.

Authors:  Lucia Caffino; Giorgio Racagni; Fabio Fumagalli
Journal:  Psychopharmacology (Berl)       Date:  2011-05-18       Impact factor: 4.530

Review 8.  Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia.

Authors:  Yael Chertkow; Orly Weinreb; Moussa B H Youdim; Henry Silver
Journal:  J Neural Transm (Vienna)       Date:  2009-07-04       Impact factor: 3.575

9.  Stress and cocaine interact to modulate basic fibroblast growth factor (FGF-2) expression in rat brain.

Authors:  Fabio Fumagalli; Laura Di Pasquale; Lucia Caffino; Giorgio Racagni; Marco Andrea Riva
Journal:  Psychopharmacology (Berl)       Date:  2007-10-04       Impact factor: 4.530

Review 10.  Neurogenic actions of atypical antipsychotic drugs and therapeutic implications.

Authors:  Samuel S Newton; Ronald S Duman
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.